Yttrium Y 90 Ibritumomab Tiuxetan
Yttrium-90 ibritumomab tiuxetan (Zevalin) is a radioimmunotherapy agent comprising a murine anti-CD20 IgG1 monoclonal antibody (ibritumomab) conjugated via the DTPA-like chelator tiuxetan to the beta-emitting radioisotope yttrium-90. It delivers targeted radiation to CD20-positive B lymphocytes and surrounding tumor cells (crossfire effect) through antibody-directed tumor localization. It is used for the treatment of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma.
治疗领域
作用机制
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Yttrium-90 ibritumomab tiuxetan (Zevalin) is a radioimmunotherapy agent comprising a murine anti-CD20 IgG1 monoclonal antibody (ibritumomab) conjugated via the DTPA-like chelator tiuxetan to the beta-emitting radioisotope yttrium-90. It delivers targeted radiation to CD20-positive B lymphocytes and surrounding tumor cells (crossfire effect) through antibody-directed tumor localization. It is used for the treatment of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Yttrium Y 90 Ibritumomab Tiuxetan is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108667. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="yttrium-y-90-ibritumomab-tiuxetan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/yttrium-y-90-ibritumomab-tiuxetan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/yttrium-y-90-ibritumomab-tiuxetan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/yttrium-y-90-ibritumomab-tiuxetan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="yttrium-y-90-ibritumomab-tiuxetan"></drugfyi-drug>